# Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors

> **NCT02078843** · PHASE1,PHASE2 · TERMINATED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 54 (actual)

## Conditions studied

- Gastroenteropancreatic Neuroendocrine Tumors

## Interventions

- **DRUG:** Gallium-68-DOTATATE PET/CT (index test)
- **DRUG:** Indium-111-Octreoscan (standard test)

## Key facts

- **NCT ID:** NCT02078843
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Superiority of one imaging method
- **Last updated:** 2016-09-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02078843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02078843, "Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02078843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*